Is Talazoparib on the market?

Talazoparib (Talazoparib) developed by Pfizer was first approved for marketing by the U.S. Food and Drug Administration (FDA) in October 2018 under the trade name Talzenna. It was approved by the European Medicines Agency (EMA) in June 2019 and approved by Health Canada in September 2020. Talazopanib is currently used to treat BRCA-mutant breast cancer and HRR-mutant prostate cancer.

Talazopanib is studied as an inhibitor of mammalian polyadenosine5'-bisphosphate ribose polymerases (PARPs), enzymes responsible for regulating basic cellular functions such as DNA transcription and DNA repair. Talazopanib was developed as a cytotoxic and antineoplastic agent. In vitro, talazopanib caused cytotoxicity in cancer cell lines defective in DNA repair genes, including BRCA1 and BRCA2. Mediated antitumor effects of talazopanib in patient-derived xenograft breast cancer models harboring mutated BRCA1 or mutated BRCA2 or wild-type BRCA1 and BRCA2.

The original drug of talazopanib has not yet been marketed in China, so it has not been included in medical insurance. The original drug specification of talazopanib listed overseas is 0.25mg*30 capsules, and the price per box may be around RMB 10,000 (the price may fluctuate due to exchange rate effects), which is relatively expensive. There are also cheaper generics of talazopanib overseas. For example, the price of a box of 1mg*30 pills produced by a Laos pharmaceutical factory may be more than 3,000 yuan (the price may fluctuate due to the exchange rate).